Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food

被引:70
作者
Abrahamsson, B [1 ]
Alpsten, M
Bake, B
Jonsson, UE
Eriksson-Lepkowska, M
Larsson, A
机构
[1] Astra Hassle AB, SE-43183 Molndal, Sweden
[2] Sahlgrens Univ Hosp, Dept Radiat Phys, S-41345 Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Dept Clin Physiol, S-41345 Gothenburg, Sweden
关键词
nifedipine; extended-release; bioavailability; food effects; gammascintigraphy;
D O I
10.1016/S0168-3659(97)00267-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of the present study was to compare the bioavailability of nifedipine when administered as a hydrophilic matrix tablet (ER) and a push-pull osmotic pump tablet (XL) administrated after fasting, and to evaluate the effect of food for the hydrophilic matrix tablet. For this purpose, three separate studies were performed on healthy volunteers (n=58) including gammascintigraphic monitoring of tablet erosion and localisation in the gastrointestinal tract for ER in one study. Both ER and XL provided almost constant drug delivery over 24 h, after administration under fasting conditions, and bioequivalence was obtained according to 90% confidence intervals of the difference between formulations within 80-125% for C-max and AUC. Food significantly increased AUC for ER but no significant difference was obtained between ER and XL with food with respect to extent of bioavailability. The rate of absorption was increased to a higher degree for ER than for XL, as indicated by a C-max which was almost twice as high for ER compared with XL. This finding was shown to be related to an increased tablet-erosion rate for ER, leading to more rapid drug release. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:301 / 310
页数:10
相关论文
共 22 条
[1]   ABSORPTION, GASTROINTESTINAL TRANSIT, AND TABLET EROSION OF FELODIPINE EXTENDED-RELEASE (ER) TABLETS [J].
ABRAHAMSSON, B ;
ALPSTEN, M ;
HUGOSSON, M ;
JONSSON, UE ;
SUNDGREN, M ;
SVENHEDEN, A ;
TOLLI, J .
PHARMACEUTICAL RESEARCH, 1993, 10 (05) :709-714
[2]  
ALDERMAN D A, 1984, International Journal of Pharmaceutical Technology and Product Manufacture, V5, P1
[3]  
ANHOFF M, 1984, J PHARM BIOMED ANAL, V2, P519
[4]   Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of C-13- and C-12-nifedipine [J].
Bode, H ;
Brendel, E ;
Ahr, G ;
Fuhr, U ;
Harder, S ;
Staib, AH .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (03) :195-201
[5]   FOOD AND NIFEDIPINE PHARMACOKINETICS [J].
CHALLENOR, VF ;
WALLER, DG ;
GRUCHY, BS ;
RENWICK, AG ;
GEORGE, CF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (02) :248-249
[6]  
Chung M, 1987, Am J Med, V83, P10, DOI 10.1016/0002-9343(87)90630-9
[7]   RELATIONSHIP BETWEEN THE RATE OF APPEARANCE OF OXPRENOLOL IN THE SYSTEMIC CIRCULATION AND THE LOCATION OF AN OXPRENOLOL OROS 16/260 DRUG DELIVERY SYSTEM WITHIN THE GASTROINTESTINAL-TRACT AS DETERMINED BY SCINTIGRAPHY [J].
DAVIS, SS ;
WASHINGTON, N ;
PARR, GD ;
SHORT, AH ;
JOHN, VA ;
LLOYD, P ;
WALKER, SM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (04) :435-443
[8]   NIFEDIPINE KINETICS AND BIOAVAILABILITY AFTER SINGLE INTRAVENOUS AND ORAL DOSES IN NORMAL SUBJECTS [J].
FOSTER, TS ;
HAMANN, SR ;
RICHARDS, VR ;
BRYANT, PJ ;
GRAVES, DA ;
MCALLISTER, RG .
JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 23 (04) :161-170
[9]  
Grundy JS, 1997, J CONTROL RELEASE, V44, P247, DOI 10.1016/S0168-3659(96)01532-5
[10]   The nifedipine gastrointestinal therapeutic system (GITS) - Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties [J].
Grundy, JS ;
Foster, RT .
CLINICAL PHARMACOKINETICS, 1996, 30 (01) :28-51